Return to Today's science sparks archives

2019-04-01

Fig. 1. Dense colonization of the intestine by K. pneumoniae preceded K. pneumoniae bacteremia. Changes in the gut microbiota of an allo-HCT patient who developed.

Fig. 1. Dense colonization of the intestine by K. pneumoniae preceded K. pneumoniae bacteremia. Changes in the gut microbiota of an allo-HCT patient who developed.
  • Jung HJ, Littmann ER, Seok R, Leiner IM, Taur Y, Peled J, van den Brink M, Ling L, Chen L, Kreiswirth BN, Goodman AL, Pamer EG

  • MBio. 2019 Mar 12;10(2). pii: e02663-18.

2019-04-02

Fig. 1 Tumor mutational burden in MET exon 14-altered lung cancers.

Fig. 1 Tumor mutational burden in MET exon 14-altered lung cancers.
  • Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A

  • Ann Oncol. 2018 Oct 1;29(10):2085-2091.

2019-04-03

Fig 1. FRα expression in human ocular tissues.

Fig 1. FRα expression in human ocular tissues.
  • Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK

  • Clin Cancer Res. 2019 Mar 15;25(6):1727-1736.
Open Access button

2019-04-04

Fig. 3. EMT progression requires AKNA to dissolve cell junctions.

Fig. 3. EMT progression requires AKNA to dissolve cell junctions.
  • Camargo Ortega G, Falk S, Johansson PA, Peyre E, Broix L, Sahu SK, Hirst W, Schlichthaerle T, De Juan Romero C, Draganova K, Vinopal S, Chinnappa K, Gavranovic A, Karakaya T, Steininger T, Merl-Pham J, Feederle R, Shao W, Shi SH, Hauck SM, Jungmann R, Bradke F, Borrell V, Geerlof A, Reber S, Tiwari VK, Huttner WB, Wilsch-Bräuninger M, Nguyen L, Götz M

  • Nature. 2019 Mar;567(7746):113-117.

2019-04-05

Fig 1. Overview of next-generation sequencing and T-cell analyses.

Fig 1. Overview of next-generation sequencing and T-cell analyses.
  • Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Sivakumar IKA, Bruhm DC, Rosner S, Phallen J, Leal A, Adleff V, Smith KN, Cottrell TR, Rhymee L, Palsgrove DN, Hann CL, Levy B, Feliciano J, Georgiades C, Verde F, Illei P, Li QK, Gabrielson E, Brock MV, Isbell JM, Sauter JL, Taube J, Scharpf RB, Karchin R, Pardoll DM, Chaft JE, Hellmann MD, Brahmer JR, Velculescu VE

  • Cancer Res. 2019 Mar 15;79(6):1214-1225.
Open Access button

2019-04-08

Fig. 1 Histopathologic and immunohistochemical features of an HNF1A-mutated HCC arising in a background of LFABP-deficient hepatic adenomatosis.

Fig. 1 Histopathologic and immunohistochemical features of an HNF1A-mutated HCC arising in a background of LFABP-deficient hepatic adenomatosis.
  • Hechtman JF, Abou Alfa GK, Stadler ZK, Mandelker DL, Roehrl MHA, Zehir A, Vakiani E, Middha S, Klimstra DS, Shia J

  • Hum Pathol. 2018 Aug 16. pii: S0046-8177(18)30308-3.

2019-04-09

Figure 3 I/R confers epigenetic HDR loss of function.

Figure 3 I/R confers epigenetic HDR loss of function.
  • Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G, Fuller JD, Ackerstaff E, Russell J, Zhang Z, Klingler S, Cho H, Kaag MG, Mazaheri Y, Rimner A, Manova-Todorova K, Epel B, Zatcky J, Cleary CR, Rao SS, Yamada Y, Zelefsky MJ, Halpern HJ, Koutcher JA, Cordon-Cardo C, Greco C, Haimovitz-Friedman A, Sala E, Powell SN, Kolesnick R, Fuks Z

  • J Clin Invest. 2019 Feb 1;129(2):786-801.
Open Access button

2019-04-10

Figure 5. Combined JAK2/MEK inhibition impacts on Jak2V617F-induced expression patterns.

Figure 5. Combined JAK2/MEK inhibition impacts on Jak2V617F-induced expression patterns.
  • Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, Dirnhofer S, Dettmer MS, Simillion C, Kaufmann BA, Chiu S, Keller M, Kleppe M, Hilpert M, Buser AS, Passweg JR, Radimerski T, Skoda RC, Levine RL, Meyer SC

  • J Clin Invest. 2019 Mar 4;130.
Open Access button

2019-04-11

Fig 1. Histones as signal integrators and cancer driver genes. a, Chromatin integrates environmental and developmental signals to control essential cell processes, including those dysregulated in cancer. b, Mechanisms and cancer type associations for known H3 oncohistone mutations. HNSCC, head and neck squamous cell carcinoma.

Fig 1. Histones as signal integrators and cancer driver genes. a, Chromatin integrates environmental and developmental signals to control essential cell processes, including those dysregulated in cancer. b, Mechanisms and cancer type associations for known H3 oncohistone mutations. HNSCC, head and neck squamous cell carcinoma.
  • Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, Kundra R, Schultz N, Muir TW, Allis CD

  • Nature. 2019 Mar;567(7749):473-478.

2019-04-12

Fig 2. Three-generation pedigrees of families with recurrent SDHA c.91C>T (p. Arg31Ter) mutation. The proband cancer diagnoses were breast cancer, renal cancer, gastrointestinal stromal tumor, neuroblastoma, gastrointestinal stromal tumor, prostate cancer, and colon cancer.

Fig 2. Three-generation pedigrees of families with recurrent SDHA c.91C>T (p. Arg31Ter) mutation. The proband cancer diagnoses were breast cancer, renal cancer, gastrointestinal stromal tumor, neuroblastoma, gastrointestinal stromal tumor, prostate cancer, and colon cancer.
  • Dubard Gault M, Mandelker D, DeLair D, Stewart CR, Kemel Y, Sheehan MR, Siegel B, Kennedy J, Marcell V, Arnold A, Al-Ahmadie H, Modak S, Robson M, Shukla N, Roberts S, Vijai J, Topka S, Kentsis A, Cadoo K, Carlo M, Latham Schwark A, Reznik E, Dinatale R, Hechtman J, Borras Flores E, Jairam S, Yang C, Li Y, Bayraktar EC, Ceyhan-Birsoy O, Zhang L, Kohlman W, Schiffman J, Stadler Z, Birsoy K, Kung A, Offit K, Walsh MF

  • Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4). pii: a002584.

2019-04-15

Fig 3. Hemispheres recover better than the vermis in Atoh1-Gli2 CKO mice.

Fig 3. Hemispheres recover better than the vermis in Atoh1-Gli2 CKO mice.
  • Wojcinski A, Morabito M, Lawton AK, Stephen DN, Joyner AL

  • Neural Dev. 2019 Feb 14;14(1):4
Open Access button

2019-04-16

Fig 1. Facilitation of immune checkpoint inhibition by chemotherapy, epigenetic therapy, and other forms of immunotherapy-scientific rationale.

Fig 1. Facilitation of immune checkpoint inhibition by chemotherapy, epigenetic therapy, and other forms of immunotherapy-scientific rationale.
  • Stahl M, Goldberg AD

  • Curr Oncol Rep. 2019 Mar 23;21(4):37.

2019-04-17

Fig 3. Generation and validation of a CCR2-Cre mouse.

Fig 3. Generation and validation of a CCR2-Cre mouse.
  • Heung LJ, Hohl TM

  • PLoS Pathog. 2019 Mar 21;15(3):e1007627.
Open Access button

2019-04-18

Figure 1. The Tfr cell transcriptional program is a combination of a Tfh and T reg cell transcriptional program.

Figure 1. The Tfr cell transcriptional program is a combination of a Tfh and T reg cell transcriptional program.
  • Hou S, Clement RL, Diallo A, Blazar BR, Rudensky AY, Sharpe AH, Sage PT

  • J Exp Med. 2019 Mar 4;216(3):605-620.

2019-04-19

Fig 2. Expression of GPRC5D protein on primary MM cells and in the hair follicle

Fig 2. Expression of GPRC5D protein on primary MM cells and in the hair follicle
  • Smith EL, Harrington K, Staehr M, Masakayan R, Jones J, Long TJ, Ng KY, Ghoddusi M, Purdon TJ, Wang X, Do T, Pham MT, Brown JM, De Larrea CF, Olson E, Peguero E, Wang P, Liu H, Xu Y, Garrett-Thomson SC, Almo SC, Wendel H, Riviere I, Liu C, Sather B, Brentjens RJ

  • Sci Transl Med. 2019 Mar 27;11(485). pii: eaau7746.

2019-04-22

Fig 6. Evolution of proliferation rate in stage IV carcinoid patients with >1 evaluable sample.

Fig 6. Evolution of proliferation rate in stage IV carcinoid patients with >1 evaluable sample.
  • Rekhtman N, Desmeules P, Litvak AM, Pietanza MC, Santos-Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, Sabari JK, Rudin CM, Ladanyi M, Klimstra DS, Travis WD, Lai WC

  • Mod Pathol. 2019 Mar 28.

2019-04-23

Figure 3. ATG16L1 binds liposomes through CCD sequences.

Figure 3. ATG16L1 binds liposomes through CCD sequences.
  • Dudley LJ, Cabodevilla AG, Makar AN, Sztacho M, Michelberger T, Marsh JA, Houston DR, Martens S, Jiang X, Gammoh N

  • EMBO J. 2019 Apr 1. pii: e100554.
Open Access button

2019-04-24

Proposed model of GSAP modulation of γ-secretase activity.

Proposed model of GSAP modulation of γ-secretase activity.
  • Wong E, Liao GP, Chang JC, Xu P, Li YM, Greengard P

  • Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6385-6390.
Open Access button

2019-04-25

Figure 6. Basic helix–loop–helix (bHLH) TFs are adversely affected by loss of TET2 in hematopoietic cells.

Figure 6. Basic helix–loop–helix (bHLH) TFs are adversely affected by loss of TET2 in hematopoietic cells.
  • Rasmussen KD, Berest I, Keβler S, Nishimura K, Simón-Carrasco L, Vassiliou GS, Pedersen MT, Christensen J, Zaugg JB, Helin K

  • Genome Res. 2019 Apr;29(4):564-575.

2019-04-26

Fig. 3 Serial changes in CTC enumeration and characterization during treatment with AZD9496 for patients with ≥5 CTC/7.5 mL WB (N = 11).

Fig. 3 Serial changes in CTC enumeration and characterization during treatment with AZD9496 for patients with ≥5 CTC/7.5 mL WB (N = 11).
  • Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF

  • Clin Cancer Res. 2018 Dec 1;24(23):5860-5872.
Open Access button

2019-04-29

Fig. 4 Na-lactate and Lactic Acid effects on HIF-1 and VEGF-A, in LDH-A KD and control NC cells.

Fig. 4 Na-lactate and Lactic Acid effects on HIF-1 and VEGF-A, in LDH-A KD and control NC cells.
  • Serganova I, Cohen IJ, Vemuri K, Shindo M, Maeda M, Mane M, Moroz E, Khanin R, Satagopan J, Koutcher JA, Blasberg R

  • PLoS One. 2018 Sep 24;13(9):e0203965.
Open Access button

2019-04-30

Key Players in TGF-β Suppression of Tumor Adaptive Immunity

Key Players in TGF-β Suppression of Tumor Adaptive Immunity
  • Batlle E, Massagué J

  • Immunity. 2019 Apr 16;50(4):924-940.

2019-05-01

Chromatin of the early zebrafish embryo lacks H3K9me3.

Chromatin of the early zebrafish embryo lacks H3K9me3.
  • Laue K, Rajshekar S, Courtney AJ, Lewis ZA, Goll MG

  • Nat Commun. 2019 Apr 4;10(1):1551.
Open Access button

2019-05-02

Figure 1. Genetic Loss of Ctla4 Leads to Aberrant T Cell Differentiation.

Figure 1. Genetic Loss of Ctla4 Leads to Aberrant T Cell Differentiation.
  • Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe'er D, Allison JP

  • Immunity. 2019 Apr 16;50(4):1084-1098.

2019-05-03

Fig. 1. Immunization schedule for SCT recipients.

Fig. 1. Immunization schedule for SCT recipients.
  • Kamboj M, Shah MK

  • Infect Dis Clin North Am. 2019 Jun;33(2):593-609.

2019-05-06

Fig. 1 Site-specific engineering of anti-HER scFv fragments and synthesis of DFO-scFv-PEG-Cy5-C’ dots.

Fig. 1 Site-specific engineering of anti-HER scFv fragments and synthesis of DFO-scFv-PEG-Cy5-C’ dots.
  • Chen F, Ma K, Madajewski B, Zhuang L, Zhang L, Rickert K, Marelli M, Yoo B, Turker MZ, Overholtzer M, Quinn TP, Gonen M, Zanzonico P, Tuesca A, Bowen MA, Norton L, Subramony JA, Wiesner U, Bradbury MS

  • Nat Commun. 2018 Oct 8;9(1):4141.
Open Access button

2019-05-07

Fig 1. Persistent chemotherapy-induced alopecia (pCIA).

Fig 1. Persistent chemotherapy-induced alopecia (pCIA).
  • Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, Paus R, Lacouture ME

  • J Am Acad Dermatol. 2019 May;80(5):1199-1213.

2019-05-08

Fig. 2 Overall survival by risk status and model in the training cohort.

Fig. 2 Overall survival by risk status and model in the training cohort.
  • Voss MH, Reising A, Cheng Y, Patel P, Marker M, Kuo F, Chan TA, Choueiri TK, Hsieh JJ, Hakimi AA, Motzer RJ

  • Lancet Oncol. 2018 Dec;19(12):1688-1698.

2019-05-09

Fig. 2: Characterization of activating mutations in MEK2, RAF1 and BRAF and their dependence on ERK signalling in histiocytoses.

Fig. 2: Characterization of activating mutations in MEK2, RAF1 and BRAF and their dependence on ERK signalling in histiocytoses.
  • Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM

  • Nature. 2019 Mar;567(7749):521-524.

2019-05-10

Figure 1. Rearrangements of the immunoglobulin loci in BL.

Figure 1. Rearrangements of the immunoglobulin loci in BL.
  • Grande BM, Gerhard DS, Jiang A, Griner NB, Abramson JS, Alexander TB, Allen H, Ayers LW, Bethony JM, Bhatia K, Bowen J, Casper C, Choi JK, Culibrk L, Davidsen TM, Dyer MA, Gastier-Foster JM, Gesuwan P, Greiner TC, Gross TG, Hanf B, Harris NL, He Y, Irvin JD, Jaffe ES, Jones SJM, Kerchan P, Knoetze N, Leal FE, Lichtenberg TM, Ma Y, Martin JP, Martin MR, Mbulaiteye SM, Mullighan CG, Mungall AJ, Namirembe C, Novik K, Noy A, Ogwang MD, Omoding A, Orem J, Reynolds SJ, Rushton CK, Sandlund JT, Schmitz R, Taylor C, Wilson WH, Wright GW, Zhao EY, Marra MA, Morin RD, Staudt LM

  • Blood. 2019 Mar 21;133(12):1313-1324.
Open Access button

2019-05-13

Fig. 5 Kang A contacts with wild-type and RifR RNAP.

Fig. 5 Kang A contacts with wild-type and RifR RNAP.
  • Peek J, Lilic M, Montiel D, Milshteyn A, Woodworth I, Biggins JB, Ternei MA, Calle PY, Danziger M, Warrier T, Saito K, Braffman N, Fay A, Glickman MS, Darst SA, Campbell EA, Brady SF

  • Nat Commun. 2018 Oct 8;9(1):4147.
Open Access button

2019-05-15

Fig 1. The pancreatic tumor microenvironment is highly immunosuppressive. Malignant cells (purple), fibroblasts, and myeloid cells in the tumor microenvironment secrete a variety of immunosuppressive cytokines and chemokines (pink text) that prevent effective antitumor CD8 T-cell responses.

Fig 1. The pancreatic tumor microenvironment is highly immunosuppressive. Malignant cells (purple), fibroblasts, and myeloid cells in the tumor microenvironment secrete a variety of immunosuppressive cytokines and chemokines (pink text) that prevent effective antitumor CD8 T-cell responses.
  • Balachandran VP, Beatty GL, Dougan SK

  • Gastroenterology. 2019 May;156(7):2056-2072.

2019-05-16

Fig 1. Examples of Tumors in Flies and Fish

Fig 1. Examples of Tumors in Flies and Fish
  • Cagan RL, Zon LI, White RM

  • Dev Cell. 2019 May 6;49(3):317-324.

2019-05-17

Fig. 1 Genomic Landscape of Myeloproliferative Neoplasms.

Fig. 1 Genomic Landscape of Myeloproliferative Neoplasms.
  • Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, Godfrey AL, Papaemmanuil E, Gundem G, MacLean C, Cook J, O'Neil L, O'Meara S, Teague JW, Butler AP, Massie CE, Williams N, Nice FL, Andersen CL, Hasselbalch HC, Guglielmelli P, McMullin MF, Vannucchi AM, Harrison CN, Gerstung M, Green AR, Campbell PJ

  • N Engl J Med. 2018 Oct 11;379(15):1416-1430.

2019-05-20

Fig 1. Imprint of pregnancy and age at first pregnancy on breast cancer biology.

Fig 1. Imprint of pregnancy and age at first pregnancy on breast cancer biology.
  • Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C

  • Breast Cancer Res. 2019 Feb 15;21(1):25.
Open Access button

2019-05-21

FIG 1. Nurses' level of clinical experience.

FIG 1. Nurses' level of clinical experience.
  • Short K, Freedman K, Matays J, Rosamilia M, Wade K

  • Clin Nurse Spec. 2019 May/Jun;33(3):123-127.

2019-05-22

FIG 1 Sequence alignment of discordant FilmArray RP and Aries BA results.

FIG 1 Sequence alignment of discordant FilmArray RP and Aries BA results.
  • McMillen T, Chow HY, Das S, Dunbar SA, Babady NE

  • J Clin Microbiol. 2019 Apr 26;57(5).

2019-05-23

Figure 1 Enoxacin boosts DDR signalling.

Figure 1 Enoxacin boosts DDR signalling.
  • Gioia U, Francia S, Cabrini M, Brambillasca S, Michelini F, Jones-Weinert CW, d'Adda di Fagagna F

  • Sci Rep. 2019 Apr 23;9(1):6460.
Open Access button

2019-05-24

Autologous lymphocyte infusion + MAGE-A3 vaccine does not induce robust CD8+ T-cell immunity.

Autologous lymphocyte infusion + MAGE-A3 vaccine does not induce robust CD8+ T-cell immunity.
  • Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ

  • Cancer Immunol Res. 2019 Apr;7(4):658-669.

2019-05-28

Fig. 3. A significant component of the infiltrate established to be of T cell lineage manifests a follicular helper T cell phenotype.

Fig. 3. A significant component of the infiltrate established to be of T cell lineage manifests a follicular helper T cell phenotype.
  • Magro CM, Ruan J, Grossman M, Hedayat AA

  • Ann Diagn Pathol. 2019 Apr 26;40:94-104.

2019-05-29

Anatomic compartments in the central nervous system.

Anatomic compartments in the central nervous system.
  • Boire A, Brandsma D, Brastianos PK, Le Rhun E, Ahluwalia M, Junck L, Glantz M, Groves MD, Lee EQ, Lin N, Raizer J, Rudà R, Weller M, Van den Bent MJ, Vogelbaum MA, Chang S, Wen PY, Soffietti R

  • Neuro Oncol. 2019 May 6;21(5):571-584.
Open Access button

2019-05-30

A hypothetical example of psychological assessment scores from 240 individuals divided into four known clusters.

A hypothetical example of psychological assessment scores from 240 individuals divided into four known clusters.
  • Li Y, Schofield E, Gönen M

  • J Math Psychol. 2019 Aug; 91:128-144.

2019-05-31

A novel AKT1 fusion–driven cancer. A, Schematic diagram of the genomic DNA, mRNA, and protein structures of the LAMTOR1–AKT1 t(11,14)(q.13.4, q32.33) fusion.

A novel AKT1 fusion–driven cancer. A, Schematic diagram of the genomic DNA, mRNA, and protein structures of the LAMTOR1–AKT1 t(11,14)(q.13.4, q32.33) fusion.
  • Slotkin EK, Diolaiti D, Shukla NN, Dela Cruz FS, Clark JJ, Gundem G, Yellapantula VD, Levine MF, You D, Ma P, Pachhal S, Ibanez Sanchez G, Benayed R, Jungbluth AA, Smyth LM, Mauguen A, Gushterova I, Ding H, Spraggon L, Darnell R, Califano A, Ladanyi M, Papaemmanuil E, Kung AL, Hyman DM, Roberts SS

  • Cancer Discov. 2019 May;9(5):605-616.

2019-06-03

Fig 2. Forest plot of modified PFS per IRF by baseline risk factor subgroups.

Fig 2. Forest plot of modified PFS per IRF by baseline risk factor subgroups.
  • Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ

  • Clin Cancer Res. 2019 Mar 15;25(6):1718-1726.
Open Access button

2019-06-04

CNCDriver Method Overview and Results in Melanoma.

CNCDriver Method Overview and Results in Melanoma.
  • Liu EM, Martinez-Fundichely A, Diaz BJ, Aronson B, Cuykendall T, MacKay M, Dhingra P, Wong EWP, Chi P, Apostolou E, Sanjana NE, Khurana E

  • Cell Syst. 2019 May 22;8(5):446-455.e8.
Open Access button

2019-06-05

Fig. 1. Overview of the bead-based radioligand binding assay.

Fig. 1. Overview of the bead-based radioligand binding assay.
  • Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS

  • Nucl Med Biol. 2019 May 3;71:32-38

2019-06-06

Fig 1.Definitions of components of chair time.

Fig 1.Definitions of components of chair time.
  • Sugalski JM1, Kubal T2, Mulkerin DL3, Caires RL4, Moore PJ5, Fiorarancio Fahy R, Gordon JN, Augustyniak CZ, Szymanski GM, Olsen M, Frantz DK, Quinn MA8, Kidd SK, Krause DM, Carlson RW, Stewart FM

  • J Oncol Pract. 2019 May;15(5):e458-e466

2019-06-07

Fig. 1. Examples of 18F-fluorodeoxyglucose (FDG)-uptake in brown adipose tissue.

Fig. 1. Examples of 18F-fluorodeoxyglucose (FDG)-uptake in brown adipose tissue.
  • Mikhaeel NG, Milgrom SA, Terezakis S, Berthelsen AK, Hodgson D, Eich HT, Dieckmann K, Qi SN, Yahalom J, Specht

  • Int J Radiat Oncol Biol Phys. 2019 Feb 11. pii: S0360-3016(19)30191-9.

2019-06-10

UEA with clear cytoplasm mimicking GCA, mitoses, and apoptotic bodies still easily visible, ×400.

UEA with clear cytoplasm mimicking GCA, mitoses, and apoptotic bodies still easily visible, ×400.
  • Turashvili G, Park KJ

  • Surg Pathol Clin. 2019 Jun;12(2):281-313.

2019-06-11

Fig 3. Severity of major toxicities. Toxicities experienced during cycle 1 of concurrent blinatumomab and tyrosine kinase inhibitor (TKI) therapy, stratified by companion TKI, including (A) cytokine release syndrome (CRS) and (B) transaminitis. PON = ponatinib, DAS = dasatinib, IMA = imatinib, NIL = nilotinib.

Fig 3. Severity of major toxicities. Toxicities experienced during cycle 1 of concurrent blinatumomab and tyrosine kinase inhibitor (TKI) therapy, stratified by companion TKI, including (A) cytokine release syndrome (CRS) and (B) transaminitis. PON = ponatinib, DAS = dasatinib, IMA = imatinib, NIL = nilotinib.
  • King AC, Pappacena JJ, Tallman MS, Park JH, Geyer MB

  • Leuk Res. 2019 Feb 23;79:27-33

2019-06-12

Fig 1. Graphical Abstract.

Fig 1. Graphical Abstract.
  • McKenney PT, Yan J, Vaubourgeix J, Becattini S, Lampen N, Motzer A, Larson PJ, Dannaoui D, Fujisawa S, Xavier JB, Pamer EG

  • Cell Host Microbe. 2019 May 8;25(5):695-705.e5.Epub 2019 Apr 25.

2019-06-13

FIG 2. Swimmer plot of patient status according to androgen receptor splice variant 7 (AR-V7) status.

FIG 2. Swimmer plot of patient status according to androgen receptor splice variant 7 (AR-V7) status.
  • Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ

  • J Clin Oncol. 2019 May 1;37(13):1120-1129.

2019-06-14

Fig 2. Examples of a true-positive and false-positive finding on conventional MRI and corresponding appearance on DWI.

Fig 2. Examples of a true-positive and false-positive finding on conventional MRI and corresponding appearance on DWI.
  • Rahbar H1, Zhang Z2, Chenevert TL3, Romanoff J2, Kitsch AE4, Hanna LG, Harvey SM, Moy L, DeMartini WB, Dogan B, Yang WT, Wang LC, Joe BN, Oh KY, Neal CH, McDonald ES, Schnall MD, Lehman CD, Comstock CE, Partridge SC

  • Clin Cancer Res. 2019 Mar 15;25(6):1756-1765.

2019-06-17

Fig 1. Scoring of IHC results for SMAD4 and TILs in the discovery cohort.

Fig 1. Scoring of IHC results for SMAD4 and TILs in the discovery cohort.
  • Wasserman I, Lee LH, Ogino S, Marco MR, Wu C, Chen X, Datta J, Sadot E, Szeglin B, Guillem JG, Paty PB, Weiser MR, Nash GM, Saltz L, Barlas A, Manova-Todorova K, Uppada SPB, Elghouayel AE, Ntiamoah P, Glickman JN, Hamada T, Kosumi K, Inamura K, Chan AT, Nishihara R, Cercek A, Ganesh K, Kemeny NE, Dhawan P, Yaeger R, Sawyers CL, Garcia-Aguilar J, Giannakis M, Shia J, Smith JJ

  • Clin Cancer Res. 2019 Mar 15;25(6):1948-1956.

2019-06-18

Fig 4. Autofluorescence (01, 04 and 07), fSHG collagen (02, 05 and 08) and bSHG collagen (03, 06 and 09).

Fig 4. Autofluorescence (01, 04 and 07), fSHG collagen (02, 05 and 08) and bSHG collagen (03, 06 and 09).
  • Natal RA, Paiva GR, Pelegati VB, Marenco L, Alvarenga CA, Vargas RF, Derchain SF, Sarian LO, Franchet C, Cesar CL, Schmitt FC, Weigelt B, Vassallo J

  • Sci Rep. 2019 May 22;9(1):7715.
Open Access button

2019-06-19

Fig 1. Exercise primes the tumor toward a more aerobic, less glycolytic physiologic microenvironment.

Fig 1. Exercise primes the tumor toward a more aerobic, less glycolytic physiologic microenvironment.
  • Zhang X, Ashcraft KA, Betof Warner A, Nair SK, Dewhirst MW

  • Cancer Res. 2019 May 15;79(10):2447-2456.

2019-06-20

Fig 1. Super-enhancer rewiring in CLL.

Fig 1. Super-enhancer rewiring in CLL.
  • Pastore A, Gaiti F, Lu SX, Brand RM, Kulm S, Chaligne R, Gu H, Huang KY, Stamenova EK, Béguelin W, Jiang Y, Schulman RC, Kim KT, Alonso A, Allan JN, Furman RR, Gnirke A, Wu CJ, Melnick AM, Meissner A, Bernstein BE, Abdel-Wahab O, Landau DA

  • Nat Commun. 2019 Apr 23;10(1):1874.
Open Access button

2019-06-21

Fig 1. Clinical information for patients with resistance to EGFR tyrosine kinase inhibitor and BRAF fusions. (A) Disease course of patient 2, who was found to have acquired resistance to osimertinib and acylglycerol kinase gene (AGK)/BRAF fusion. (B) Disease course of patient 4, who was found to have acquired resistance to erlotinib and progressive mediastinal disease with AGK/BRAF fusion.

Fig 1. Clinical information for patients with resistance to EGFR tyrosine kinase inhibitor and BRAF fusions. (A) Disease course of patient 2, who was found to have acquired resistance to osimertinib and acylglycerol kinase gene (AGK)/BRAF fusion. (B) Disease course of patient 4, who was found to have acquired resistance to erlotinib and progressive mediastinal disease with AGK/BRAF fusion.
  • Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M

  • J Thorac Oncol. 2019 May;14(5):802-815.

2019-06-24

Fig 1. Radiation-induced cardiovascular disease.

Fig 1. Radiation-induced cardiovascular disease.
  • Lee Chuy K, Nahhas O, Dominic P, Lopez C, Tonorezos E, Sidlow R, Straus D, Gupta D

  • Curr Treat Options Cardiovasc Med. 2019 Jun 4;21(7):31.

2019-06-25

Fig. 2. Adult genitourinary RMS: immunohistochemistry.

Fig. 2. Adult genitourinary RMS: immunohistochemistry.
  • Gupta S, Sosa CP, Kosari F, Folpe A, Bhinge KN, Yang L, Agahi A, Johnson SH, Frank I, Boorjian SA, Hansel DE, Al-Ahmadie HA, Reuter VE, Vasmatzis G, Jimenez RE, Herrera-Hernandez L, Cheville JC

  • Hum Pathol. 2019 June;88:48-59

2019-06-26

Fig. 1 Contouring and plan evaluation.

Fig. 1 Contouring and plan evaluation.
  • Reyngold M, Parikh P, Crane CH

  • Radiat Oncol. 2019 Jun 6;14(1):95.
Open Access button

2019-06-28

Figure 1. CD103+CD11b− DCs are essential for CD8+ T cell immunosurveillance and partially mediate the antitumor effects of imatinib in GIST.

Figure 1. CD103+CD11b− DCs are essential for CD8+ T cell immunosurveillance and partially mediate the antitumor effects of imatinib in GIST.
  • Medina BD, Liu M, Vitiello GA, Seifert AM, Zeng S, Bowler T, Zhang JQ, Cavnar MJ, Loo JK, Param NJ, Maltbaek JH, Rossi F, Balachandran V, DeMatteo RP

  • J Exp Med. 2019 Jun 3;216(6):1359-1376.

2019-07-01

Fig 2. Response of patients with epithelial ovarian cancer by germline BRCA mutation status

Fig 2. Response of patients with epithelial ovarian cancer by germline BRCA mutation status
  • Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA

  • Lancet Oncol. 2019 Apr;20(4):570-580.